China Oncology Market - Forecast(2024 - 2030)

Report Code: HCR 1315 Report Format: PDF + Excel
1. China Oncology Market Overview
2. China Oncology Market Executive Summary
3. China Oncology Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis 
3.2.1. Product Benchmarking
3.2.2. End User profiling
4. China Oncology Market Forces
4.1. Market Drivers
4.2. Market Constraints & Challenges
4.3. Attractiveness of the Industry
4.3.1. Power of Suppliers
4.3.2. Power of Customers
4.3.3. Threat of New entrants
4.3.4. Threat of Substitution
4.3.5. Degree of Competition
5. China Oncology Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Opportunities Analysis
5.3. Market Life Cycle Analysis
6. China Oncology Market – By Cancer Type
6.1. Introduction
6.2. Breast Cancer
6.3. Lung Cancer
7. China Oncology Market - By Therapy Type
7.1. Introduction
7.2. Medical Oncology 
7.2.1. Chemotherapy
7.2.2. Targeted Therapy
7.2.3. Immunotherapy (biologics therapy)
7.2.4. Hormonal Therapy
7.2.5. Others
7.2.5.1. Blood and Platelet Transfusions
7.2.5.2. Investigational Therapy
7.3. Radiation Oncology
7.3.1. External Radiation Therapy
7.3.2. Internal Radiation Therapy
7.4. Surgical Oncology
7.4.1. Laparoscopic Surgery 
7.4.2. Robotic Surgery 
8. China Oncology Market Entropy
9. China Oncology Market Company Profiles
9.1. CStone Pharmaceuticals 
9.2. InnoCare Pharma
9.3. Adlai Nortye
9.4. Chi-Med
9.5. BeiGene
9.6. Company 6
9.7. Company 7
9.8. Company 8
9.9. Company 9
9.10. Company 10
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Bibliography
10.5. Compilation of Expert Insights